申请人:Kyowa Hakko Kogyo Co., Ltd.
公开号:US06222035B1
公开(公告)日:2001-04-24
[1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A2A receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A2A receptors (for example, Parkinson's disease or senile dementia):
wherein R1 represents substituted or unsubstituted aryl, or the like; R2 represents hydrogen, halogen, lower alkyl, substituted or unsubstituted aryl, or the like; R3 represents hydrogen, halogen, XR10 (wherein X represents O or S; and R10 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aralkyl, lower alkyl, or hydroxy lower alkyl), or the like; and Q represents hydrogen or 3,4-dimethoxybenzyl.
提供了由式(I)表示的或其药学上可接受的盐所代表的[1,2,4]三唑[1,5-c]嘧啶衍生物,其具有腺苷A2A受体拮抗作用,并可用于治疗或预防由腺苷A2A受体过度活化引起的各种疾病(例如,帕金森病或老年性痴呆症):其中R1代表取代或未取代的芳基等;R2代表氢、卤素、较低烷基、取代或未取代的芳基等;R3代表氢、卤素、XR10(其中X代表O或S;R10代表取代或未取代的芳基、取代或未取代的芳香杂环环、取代或未取代的芳基烷基、较低烷基或羟基较低烷基)等;Q代表氢或3,4-二甲氧基苄基。